Glow LifeTech (TSE:GLOW)
:GLOW
Want to see TSE:GLOW full AI Analyst Report?
GLOW Stock Chart & Stats
C$0.06
>-C$0.01(-7.69%)
At close: 4:00 PM EST
C$0.06
>-C$0.01(-7.69%)
Day’s Range― - ―
52-Week RangeC$0.05 - C$0.08
Previous CloseN/A
Volume6.00K
Average Volume (3M)266.05K
Market Cap
C$8.15M
Enterprise ValueC$6.84M
Total Cash (Recent Filing)C$1.37M
Total Debt (Recent Filing)C$56.19K
Price to Earnings (P/E)―
Beta0.48
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding181,160,580
10 Day Avg. Volume165,602
30 Day Avg. Volume266,047
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)3.82
Price to Sales (P/S)5.04
P/FCF Ratio-87.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe company’s revenue more than doubled year-over-year, demonstrating accelerating commercial traction from a small base. Sustained top-line growth supports future margin expansion and economies of scale, improving the odds of moving toward sustained profitability over the next several quarters.
Improving Cash BurnOperating cash flow improving to near breakeven reflects stronger working-capital management or disciplined spending. A materially reduced burn rate extends runway and reduces near-term financing pressure, giving management time to convert revenue momentum into positive cash generation.
Low Leverage And Positive EquityVery low debt and positive equity provide financial flexibility for an early-stage biotech, lowering solvency risk and preserving capacity to fund R&D or commercialization. This balance-sheet position supports strategic options without immediate reliance on dilutive financing.
Bears Say
Persistent Operating LossesOngoing operating losses show the cost base still outstrips current revenue and limit the firm's ability to internally fund growth. Persistent negative EBIT/EBITDA means management must either improve margins or secure external capital, creating execution risk over the medium term.
Negative Free Cash FlowAlthough burn has improved, free cash flow remains negative, indicating the business is not yet self-sustaining. Continued negative FCF necessitates external funding to support operations or growth, which can dilute shareholders or constrain strategic investment if markets tighten.
Negative Returns & Balance-Sheet SensitivityNegative ROE and volatile equity levels signal limited internal capital generation and sensitivity to operating swings. For an early-stage biotech this raises the likelihood of future equity issuance or dilution to fund development, increasing shareholder dilution risk over time.
Glow LifeTech News
GLOW FAQ
What was Glow LifeTech’s price range in the past 12 months?
Glow LifeTech lowest stock price was C$0.04 and its highest was C$0.07 in the past 12 months.
What is Glow LifeTech’s market cap?
Glow LifeTech’s market cap is C$8.15M.
When is Glow LifeTech’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Glow LifeTech’s earnings last quarter?
Currently, no data Available
Is Glow LifeTech overvalued?
According to Wall Street analysts Glow LifeTech’s price is currently Overvalued.
Does Glow LifeTech pay dividends?
Glow LifeTech does not currently pay dividends.
What is Glow LifeTech’s EPS estimate?
Glow LifeTech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Glow LifeTech have?
Glow LifeTech has 181,160,580 shares outstanding.
What happened to Glow LifeTech’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Glow LifeTech?
Currently, no hedge funds are holding shares in TSE:GLOW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Glow LifeTech
Glow Lifetech Corp., a biotechnology company, focuses on producing nutraceutical and cannabinoid-based products in North America. The company engages in the commercialization of two technologies, such as MyCell Enhanced technology, a nutraceutical and cannabis nutrient delivery technology; and a cannabis Smart Consumption System to assist users and patients to store, journal, control, consume, and manage cannabis related products. The company has the exclusive North American rights for the production, sale, and distribution rights for the certain micellization technology for cannabis and hemp derived ingredients, curcumin, vitamin K, and iron. It also engages in the business of secondary processing of ingredients to produce micellized materials from certain vitamins, nutraceuticals, and cannabis extracts that makes fat-soluble substances available for immediate absorption into the body reach near 100% bioavailability and water compatibility. The company was incorporated in 2018 and is based in Toronto, Canada.
Technical Analysis
COSCIENS Biopharma
―
Kane Biotech
―
Quest Pharmatech
―
PreveCeutical Medical
―
PharmAla Biotech Holdings, Inc.
―
Options Prices
Currently, No data available
---